Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sensa supports weight-loss claims

This article was originally published in The Tan Sheet

Executive Summary

Supplement marketer Sensa Products substantiates claims its weight-loss product Sensa "works with your body's natural impulses" and "was proven effective in one of the largest clinical studies ever performed on a non-prescription weight-loss product," the National Advertising Division says in a report Sept. 3. The Council of Better Business Bureaus division notes a clinical study of the weight-loss product included 1,436 participants who lost an average of 30.5 pounds in six months as advertised. NAD recommends the firm discontinue testimonials on Sensa's Web site that say people who took Sensa lost 70 or 120 pounds. NAD says the testimonials are misleading when paired with claims based on studies. Manhattan Beach, Calif.-based Sensa says it will consider NAD's recommendation

You may also be interested in...

Creating Stability In a Time of Transition

UK-centric investment firm Syncona’s model of “founding, building and funding” early-stage biotech companies – with a commitment to the longer term – hopes to help make Great Britain a cell and gene therapy powerhouse.

Regulatory Measures Could Mitigate EU Coronavirus Risks

As part of its response to the coronavirus outbreak, Medicines for Europe has set out a series of policy recommendations that it says could help to mitigate the risks of COVID-19.

EU Off-Patent Industry Sees ‘Limited Immediate Risk’ From COVID-19

 The coronavirus COVID-19 outbreak poses a “limited immediate risk” to European production and supplies of off-patent drugs, according to industry association Medicines for Europe. However, if the situation continues for an extended period an “important impact” cannot be ruled out.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts